BTAI icon

BioXcel Therapeutics
BTAI

Overview Fund Activity

20 hedge funds and large institutions have $34.2M invested in BioXcel Therapeutics in 2018 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 5 increasing their positions, 6 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
20
Holders Change
-2
Holders Change %
-9.09%
% of All Funds
0.46%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
6
Increased
5
Reduced
6
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
AIM
Artemis Investment Management
United Kingdom
+$257K
2
BlackRock
BlackRock
New York
+$137K
3
Millennium Management
Millennium Management
New York
+$137K
4
Point72 Asset Management
Point72 Asset Management
Connecticut
+$58.4K
5
Vanguard Group
Vanguard Group
Pennsylvania
+$53.3K

Top Sellers

1
Barclays
Barclays
United Kingdom
-$6.33M
2
AC
Ascend Capital
California
-$2.05M
3
MIM
Monashee Investment Management
Massachusetts
-$922K
4
MWNA
Marshall Wace North America
New York
-$428K
5
California Public Employees Retirement System
California Public Employees Retirement System
California
-$275K
Name Holding Trade Value Shares
Change 		Shares
Change %
CCA
26
Catalyst Capital Advisors
New York
– -$5K -28 Closed
TRCT
27
Tower Research Capital (TRC)
New York
– -$1K -6 Closed
1
2